Background: Recent studies have suggested associations between statins and enhanced survival among patients with pancreatic ductal adenocarcinoma (PDAC). However, the relationship between statins, cholesterol, and survival remains unclear. Methods: We conducted a retrospective cohort study on 2142 PDAC patients in a regional integrated healthcare system from 2006 to 2014. Electronic pharmacy records were used to abstract information on the type, length, and dosage of statin exposures starting in the year prior to diagnosis. The cumulative and individual effects of simvastatin, lovastatin, atorvastatin, pravastatin, and rosuvastatin on mortality were assessed using Cox proportional hazards regression. Statins were evaluated as any use (pre-and postdiagnosis as a time-dependent variable) and baseline use (prediagnosis only). We also evaluated whether low-density lipoprotein (LDL) cholesterol, measured at various time windows prior to diagnosis, had an independent influence on survival. Additional analyses were performed to examine whether cholesterol mediated the relationship between statins and mortality. All models included age, race, stage, surgery, gemcitabine-based chemotherapy, and the Charlson comorbidity index as covariates. Results: Any (hazard ratio [HR] ¼ 0.87, 95% confidence interval [CI] ¼ 0.79 to 0.97) and baseline (HR ¼ 0.88, 95% CI ¼ 0.79 to 0.98) statin use were both associated with a decreased risk in mortality. When assessing individual statins, we found reduced mortality among simvastatin (HR ¼ 0.87, 95% CI ¼ 0.77 to 0.98) and atorvastatin (HR ¼ 0.58, 95% CI ¼ 0.46 to 0.72) users. Cholesterol was not associated with mortality and did not mediate any relationships between statins and survival. Conclusions: Statin use rather than cholesterol level was associated with lower mortality risk in patients with pancreatic cancer. Statins appear to improve survival through a lipid-independent mechanism.
Pancreatic ductal adenocarcinoma (PDAC) presents a substantial challenge. It is one of the most lethal cancers, with a fiveyear survival of only 8%, which is the lowest survival rate among the cancers reported by the American Cancer Society (1) . Pancreatic cancer is presently the fourth leading cause of cancer-related mortality in the United States and is estimated to eventually surpass colorectal cancer as the second leading cause of cancer-related deaths by 2030 (2) . Existing treatment for pancreatic cancer provides only modest survival benefit.
Thus, alternative therapies that may enhance pancreatic cancer survival are urgently needed.
HMG-CoA reductase inhibitors or statins, traditionally prescribed for lipid-lowering effects and cardiovascular disease prevention, have become a drug of interest for their anticancer properties. At the molecular level, statins have been found to reduce inflammation, inhibit angiogenesis, induce cellular apoptosis, and suppress proliferation (3) . Given these pleiotropic effects, statins have been widely evaluated for their protective effects in many cancers. In a systematic review of 41 observational studies, statins were associated with improved survival in breast, prostate, colorectal, ovarian, and urothelial tract cancers (4) .
The impact of statin use has only recently been investigated in pancreatic cancer (5) (6) (7) (8) (9) (10) . In a previous study from our institution, we found that simvastatin was associated with enhanced survival among patients with early-stage pancreatic cancer (6) . Statins have also been associated with reduced mortality in a cohort of elderly Medicare pancreatic cancer patients (7) . Despite these promising results, these studies have limited generalizability given their selective patient populations. Moreover, they do not delineate whether these protective benefits are consequences of statin use or improved cholesterol control.
The objective of the current study was to further characterize the relationship between statin use and mortality in a heterogeneous population of individuals with pancreatic cancer. Specifically, we aimed to explore the influence of statins across varying agents and exposure levels. Additionally, we sought to elucidate whether statins acted through a lipid-mediated or potentially alternate mechanism.
Methods

Study Population
We conducted a retrospective cohort study of patients with pancreatic ductal adenocarcinoma diagnosed at Kaiser Permanente Southern California (KPSC) from 2006 to 2014. KPSC is an integrated health system that serves over 4 million members across Southern California. KPSC provides care to a socio-economically diverse population through a network of 15 medical centers and 200 medical offices. Members receive complete medical coverage, including pharmaceutical benefits, upon enrollment.
Study patients were identified from KPSC's internal cancer registry. The registry maintains comprehensive records on each cancer patient, including information on demographics, tumor staging, histology, treatment, and mortality. Individuals were included in the study if they were age 18 years or older at diagnosis, were active members, and had at least one year of continuous membership prior to diagnosis. Those with nonadenocarcinoma histology, unknown cancer stage, or previous pancreatic cancer diagnosis were excluded from the study cohort (Figure 1 ). This study was approved by the institutional review board (IRB) of KPSC. Signed consent was waived by the IRB as the study involved no more than minimal risk to the patients.
Statin Exposures
Electronic pharmacy records were assessed to determine statin exposure starting in the year prior to diagnosis. These records included information on the type, dispensation dates, dosage, and day supply of each statin prescription. We obtained records on all simvastatin, lovastatin, atorvastatin, pravastatin, and rosuvastatin dispensations. Patients were assumed to have continued use of statins during the entire duration of the prescription (eg, a 90-day supply corresponded to 90 days of statin use). Records were consolidated if there were 30 or fewer days between the end of one dispensation and the start of the following dispensation.
Individuals were considered any users if they filled any statin prescriptions starting in the year before diagnosis to the end of follow-up. Any use was assessed as a time-dependent exposure to account for potential immortal time bias. Statin users at ARTICLE diagnosis were assigned as exposed for the entire follow-up period, while those starting statins after diagnosis were treated as unexposed until their first prescription. Any use exposures were defined as overall use (any vs no statin) and type of statin (specific statin vs no statin). We also categorized patients as baseline users if had any statin dispensations in the year prior to diagnosis. Baseline exposures were evaluated as overall use, type of statin, and duration (less than six months, six to nine months, nine to 12 months vs no statin).
Cholesterol Exposures
Serum low-density lipoprotein (LDL) cholesterol measurements were obtained from the electronic medical record. The average of all measurements in certain time windows (one year or less, one to three years, three to five years) prior to diagnosis was calculated for each patient. Mean LDL was dichotomized as optimal (<100 mg/dL) vs nonoptimal (100 mg/dL) and further categorized as optimal (<100 mg/dL), near optimal (100-129 mg/ dL), and borderline high/high (130 mg/dL), according to the Adult Treatment Panel III guidelines from the National Cholesterol Education Program (11) .
Assessment of Other Covariates
Information on cancer stage and surgical treatment was obtained from the KPSC cancer registry. Stage was categorized into localized/regional (stage I-III) and distant (stage IV) to account for an imbalanced distribution. Receipt of gemcitabinebased chemotherapy was ascertained from electronic health records. Charlson comorbidity index was calculated using all diagnosis codes in the year prior to diagnosis.
Outcome
We evaluated overall survival from diagnosis date until the end of follow-up on April 30, 2015. Patients were censored at death, last contact, or end of study. Death dates were obtained from the internal cancer registry, inpatient records, and the California state death index.
Statistical Analyses
Baseline characteristics were compared across statin use using the chi-square test for categorical variables, t test for continuous variables, and log-rank test for survival time.
The impact of statins on mortality was evaluated using Cox proportional hazards regression. Any statin use was assessed as a time-dependent variable in two models for overall use and type of statin. Baseline exposures were assessed in three separate models for overall use, type of statin, and length of use.
We ran additional models to investigate whether cholesterol measured at various time windows (one year or less, one to three years, three to five years) before diagnosis had an influence on mortality. For each time window, we analyzed cholesterol as a continuous (per 30 mg/dL increase), dichotomous (optimal vs nonoptimal), and categorical (optimal, near optimal, borderline high/high) variable. These analyses were done separately for statin users and nonusers.
Furthermore, we refit the statin models with cholesterol as an additional predictor to assess whether cholesterol mediated the relationship between statins and survival. For these analyses, we used the continuous, dichotomous, and categorical cholesterol values measured within the year prior to diagnosis.
We performed a number of sensitivity analyses to control for potential biases. Because end-of-life decisions may influence medication use, we fit models with statin exposure lagged by one month to eliminate possible reverse causation. The lagged exposure analyses were restricted to individuals who survived at least one month after diagnosis. We also controlled for the healthy user effect because medication users may be more likely to seek out screening and medical care than nonusers. We addressed this bias by selecting controls among users of proton pump inhibitors (PPIs), a type of medication used to treat several gastrointestinal conditions. To account for missing cholesterol data, we imputed values from previous time windows and also fit models with an indicator for missing cholesterol. Results were unchanged using both methods, so we proceeded with a complete case analysis.
All models were adjusted for age, race, stage, receipt of surgery, receipt of gemcitabine-based chemotherapy, and Charlson comorbidity index. Additional analyses within subgroups of sex, race, stage, and receipt of chemotherapy were conducted to assess effect measure modification of the impact of statins on survival. Schoenfeld residuals were used to verify the proportional hazards assumption, while Martingale and deviance residuals were used to assess model fit. All analyses were twosided and performed using SAS 9.3 (Cary, NC). P values of less than .05 were considered statistically significant.
Results
Baseline Characteristics
The study cohort consisted of 2142 patients diagnosed with pancreatic cancer from 2006 to 2014. Among these patients, 1167 (54.5%) had metastatic disease, 1077 (50.3%) received chemotherapy, and 409 (19.1%) received surgical treatment (Table  1 ). There were 1625 (75.9%) reported deaths, with a median survival time of 4.6 months (interquartile range [IQR] ¼ 1.7-10.5 months).
Statin use was observed in 1155 (53.9%) patients; 1127 (97.6%) started statins before diagnosis and 28 (2.4%) started after diagnosis. Among statin users, simvastatin (61.6%), lovastatin (19.7%), and atorvastatin (15.6%) were the most common medications (Table 2) . Compared with nonusers, individuals on statin treatment were older, less likely to be female, less likely to have metastatic disease, and had higher Charlson scores. Median survival times did not differ between statin users (4.6 months, IQR ¼ 1.6-10.3 months) and nonusers (4.7 months, IQR ¼ 1.8-10.8 months) in univariate analysis (log-rank test, P ¼ .99) ( Table 1) .
LDL cholesterol values were available for 2042 (95.3%) individuals, who had roughly six measurements each. The average of the mean LDL measurement in the year prior to diagnosis was higher in nonusers (116.6 mg/dL) than in statin users (93.6 mg/dL; t test, P < .001) ( Table 1) . Nonoptimal cholesterol levels were observed more frequently in nonusers (64.5%) than in users (32.5%; chi-square test, P < .001).
Impact of Statin Use on Mortality
Compared with nonusers, individuals who used any statins during the study period had a 13% decrease in the risk for mortality (hazard ratio [HR] ¼ 0.87, 95% CI ¼ 0.79 to 0.97) ( Table 3) . Among the individual statins, only simvastatin (HR ¼ 0.87, 95% CI ¼ 0.77 to 0.98) and atorvastatin (HR ¼ 0.58, 95% CI ¼ 0.46 to 0.72) had independent effects on survival (Table 4) .
Patients with baseline exposure had a 12% reduction in mortality risk (HR ¼ 0.88, 95% CI ¼ 0.79 to 0.98) ( Table 4 ). There was also improved survival for those who used statins for nine to 12 months (HR ¼ 0.86, 95% CI ¼ 0.76 to 0.96), but no difference for those using statins less than nine months compared with non users (P trend ¼ .007). Simvastatin (HR ¼ 0.83, 95% CI ¼ 0.74 to 0.94) and atorvastatin (HR ¼ 0.75, 95% CI ¼ 0.60 to 0.94) were again the only two medications that were independently associated with improved survival.
Impact of Cholesterol on Mortality
For both statin users and nonusers, we found no associations between survival and cholesterol measured in any time window before diagnosis. Cholesterol did not influence the risk for mortality regardless of whether it was evaluated as a continuous, dichotomous, or categorical variable (Table 5) .
Mediation by Cholesterol
The association between statins and mortality did not appear to be mediated by cholesterol in any analyses. After including the continuous cholesterol measurement as an additional covariate in the models, any (HR ¼ 0.86, 95% CI ¼ 0.77 to 0.97) and baseline (HR ¼ 0.87, 95% CI ¼ 0.78 to 0.98) statin use were still associated with improved survival (data not shown). The results using the dichotomous and categorical cholesterol measurements were virtually unchanged and are not presented here.
Sensitivity Analyses
Lagging exposures by one month to account for reverse causation had minimal influence on the relationship between statins and survival. For the 1825 patients (85.2% of original cohort) who survived more than one month, overall statin use was associated with a 12% decrease in mortality risk (HR ¼ 0.88, 95% CI ¼ 0.79 to 0.99) ( 
Effect Measure Modification
There was no effect measure modification of the relationship between any statin use and survival across gender (P interaction ¼ .30), race (P interaction ¼ .25), stage (P interaction ¼ .84), or receipt of gemcitabine-based chemotherapy (P interaction ¼ .36; data not shown). Likewise, gender (P interaction ¼ .40), race (P interaction ¼ .35), stage (P interaction ¼ .73), and chemotherapy (P interaction ¼ .55) did not modify the influence of baseline statin use on mortality (data not shown).
Discussion
In this retrospective longitudinal cohort study, we found that statin use was independently associated with improved survival among a heterogeneous population of pancreatic cancer patients. This association was observed for both any and baseline statin use and was still present after controlling for reverse causation and the healthy user effect. Our analysis further revealed that cholesterol did not have an independent influence on survival or mediate the relationship between statins and mortality. These results indicate that the observed benefit of statin use is not derived through a lipid-lowering pathway.
Statins have previously received attention for their potential protective role against the development of pancreatic cancer. While a meta-analysis of 12 studies did not support an association between statins and pancreatic cancer risk (12) , there is growing evidence that statins may rather benefit patients with existing disease. In our prior study, we found that statins were associated with prolonged survival in early-stage patients undergoing surgery (6) . These results are consistent with two past ARTICLE studies that found a favorable effect of statins in individuals with surgically resectable tumors (7, 9) . However, a majority of patients with pancreatic cancer are diagnosed at advanced stages, for which the relationship between statins and survival is not as well characterized. The present study helps narrow this gap in evidence by conducting a comprehensive assessment of statin exposures in pancreatic cancer patients in all stages and across various individual characteristics. From our analysis, we found that simvastatin and atorvastatin were the only two statins that were independently associated with reduced mortality. This may be explained by the fact that atorvastatin and simvastatin are among the higher potency statins (13) . Atorvastatin and simvastatin have also been associated with improved survival in previous settings. In both our previous study and the Medicare analysis, simvastatin was the sole statin that was associated with enhanced survival (6, 7) . In addition, simvastatin and atorvastatin were associated with survival in pancreatic cancer patients in Korea (8) .
We also observed greater survival in individuals who had longer durations of statin use. Because most statin users had kDichotomous: optimal (<100 mg/dL), nonoptimal (100 mg/dL). ¶Categorical: optimal (<100 mg/dL), near optimal (100-129 mg/dL), borderline high/high (130 mg/dL).
#Two-sided Ptrend value. (8) . Together, these results provide further evidence that stronger potency and longer periods of use may have the greatest effect on survival.
Our study aimed to explicate the interconnected relationship between statins, cholesterol, and mortality in pancreatic cancer patients. We found that cholesterol had no influence on survival among both statin users and nonusers, regardless of when it was measured and how it was analyzed. While there is evidence that high cholesterol increases pancreatic cancer risk (14) , this harmful influence does not seem to translate toward mortality. Cholesterol and pancreatic cancer survival have not been well evaluated, and previous studies have had incongruous results (15, 16) .
We also observed no mediation of cholesterol in any of the statin analyses, suggesting that statins may attenuate oncogenesis and tumor progression through a lipid-independent mechanism. There are a number of proposed pathways for the antineoplastic effect of statins. Statins inhibit HMG-CoA reductase and consequently the prenylation of proteins, such as Ras and Rho, that are required for cell cycle activation and cell proliferation (17) . There is in vivo evidence from pancreatic cancer mouse models that simvastatin and atorvastatin prevent activation of the K-ras proto-oncogene, which is commonly mutated in pancreatic cancer tumors (18) (19) (20) . Statins have also been found to suppress epidermal growth factor-induced cancer cell invasion by attenuating the cytosol-to-membrane translocation of RhoA (21) . Several other in vitro studies have further demonstrated that statins can induce apoptosis by targeting enzymes such as caspase, extracellular signal-regulated kinase (ERK), and survivin (22) .
A major strength of this study is its setting. The use of data from an integrated health care system allowed for detailed individual-level longitudinal follow-up over a nine-year period. Because we had exact medication dispensation dates and dosages from our electronic pharmacy records, we were able to delineate actual initiations of statin use and conduct both a baseline and time-varying analysis of statin exposures. We also had comprehensive serum LDL measurements over the entire study period, which permitted us to obtain a more accurate representation of each patient's cholesterol status at various time windows. As our sample was relatively large and diverse, our findings have more external generalizability compared with previous studies.
Despite these strengths, one limitation was that we were unable to ascertain if patients were actually taking their prescribed statins. Utilizing the pharmacy data helped avoid recall bias, but could have overestimated statin use. Additionally, we could not assess statin exposure in each individual disease stage because of an inadequate sample of earlier-stage patients. Because 97.6% of statin users had baseline exposure, our sample was also insufficiently powered to evaluate the effect of statin therapy initiated after diagnosis. Moreover, while our analytical approaches controlled for several biases, we could not rule out residual confounding.
In summary, simvastatin and atorvastatin were independently associated with improved survival in this retrospective cohort of patients with pancreatic cancer. Based on our analysis, we conclude that the observed effect of statins is mediated through a lipid-independent pathway. Future studies are needed to characterize the mechanisms of statin therapy, namely its chemosensitizing properties and synergistic effects with agents such as metformin and aspirin (23) . Given their wide availability and relatively safe side-effect profile in comparison with current chemotherapeutic agents, statins may prove to be a promising adjunctive treatment option for patients with pancreatic cancer.
Funding
